When a top melanoma researcher is told he has an aggressive brain tumour, most people would stop and rest. Professor Richard Scolyer instead turned his own diagnosis into a public research project — one that held his cancer back for nearly two years, opened a new line of attack against glioblastoma, and ended only with his death on June 7, 2026, at age 59, leaving behind a clinical trial, a family, and a changed conversation about brain cancer (BBC News (UK public broadcaster)).
Born: 1966 ·
Died: 2026 ·
Profession: Professor of melanoma research ·
Known for: Transforming melanoma care with immunotherapy ·
Diagnosis: Glioblastoma
Quick snapshot
- Diagnosed with glioblastoma, an aggressive brain cancer (The Scientist (life-science magazine))
- Died in 2026 after a battle with cancer (SBS News (multilingual broadcaster))
- Named the 2024 Australian of the Year (SBS News (multilingual broadcaster)) (The Scientist (life-science magazine))
- His wife’s profession — not disclosed in the family’s open letter
- Ages of his three children — not disclosed in the family’s open letter
- Which parts of the experimental protocol will help other patients
- Given an initial prognosis of six to eight months (ABC News (Australian public broadcaster))
- First patient to receive neoadjuvant combination immunotherapy for glioblastoma (The Pathologist (pathology industry publication))
- A clinical trial is being created to adapt the glioblastoma treatment program (The Conversation (academic analysis site))
- Prime Minister Anthony Albanese offered a state funeral (SBS News (multilingual broadcaster)) (The Conversation (academic analysis site))
Six facts capture the arc: a pathologist’s training, a researcher’s breakthrough, and a patient’s experiment.
| Field | Detail |
|---|---|
| Full name | Professor Richard Scolyer AO |
| Born | 1966 |
| Died | 2026 |
| Known for | Melanoma research and immunotherapy |
| Diagnosis | Glioblastoma |
| Notable role | Co-Medical Director, Melanoma Institute Australia |
Who is Professor Richard Scolyer?
Scolyer was not a person who became famous first and accomplished things later. The work came before the diagnosis.
Early career and education
- He was a pioneering melanoma pathologist and researcher (9News (Australian news channel))
- He held a professorship in melanoma research at the University of Sydney (9News (Australian news channel))
- He served as Co-Medical Director of the Melanoma Institute Australia (9News (Australian news channel))
Scolyer built that reputation one slide at a time, reading melanoma cells under a microscope while the field’s treatment options were still thin. His later work with clinician-scientist Georgina Long made him a central figure in the immune-therapy era.
The scale of that contribution became clear when his own treatment drew on it: the melanoma breakthroughs he and Long helped build became the scientific base for the experimental brain cancer protocol he received.
Key achievements in melanoma research
The pathologist who spent his career reading other people’s cancer cells became the first glioblastoma patient to receive a combination-immunotherapy protocol — and he documented the experiment as he lived it.
His lab work and his public role were never separate. When the experimental brain cancer protocol was revealed, it was read as a direct extension of the melanoma research he had spent decades building.
The implication: Scolyer understood melanoma from the inside of the pathology lab. When his own diagnosis proved to be one of the most aggressive in medicine, he had exactly the skills needed to turn a private tragedy into a public protocol.
When was Richard Scolyer diagnosed?
The date matters because it marks the moment the private story became a public one.
Diagnosis announcement
- He was diagnosed with grade four glioblastoma in June 2023 (The Scientist (life-science magazine))
- He announced the diagnosis publicly on his Facebook blog (Richard Scolyer’s Facebook page (personal blog))
Glioblastoma is one of the most aggressive brain cancers, and Scolyer did not treat the diagnosis as a private matter. By posting the news himself, he turned a clinical event into a public record.
Initial reactions
- The Times described him as “his own guinea pig” in its obituary (The Times (UK newspaper))
The shift was fast. Rather than settle into the standard treatment path for glioblastoma, Scolyer and his team began designing a plan that drew directly on the melanoma research they had spent years building.
The takeaway: the diagnosis arrived with a short clock attached, and Scolyer’s first public move was to turn that clock into a research variable.
What treatment did Professor Richard Scolyer receive for brain cancer?
The protocol was built from melanoma research and aimed at one of the most aggressive cancers in medicine.
Therapeutic approach
- He was the first patient to receive neoadjuvant combination immunotherapy for glioblastoma (The Pathologist (pathology industry publication))
- The protocol used simultaneous doses of three checkpoint inhibitors before surgery (The Conversation (academic analysis site))
- Surgery to remove as much tumour as possible followed 12 days after the treatment began (The Conversation (academic analysis site))
The design was borrowed directly from melanoma practice: give immune drugs first, then operate. The sequence was the research question.
Role of immunotherapy
Nearly two years of stability against a prognosis of months is a milestone, not a cure. The trial now adapting the protocol will decide whether the response was a single-patient event or a repeatable result.
Against a prognosis of six to eight months, the treatment was reported to delay the disease for nearly two years (ABC News (Australian public broadcaster)). That gap between forecast and outcome is why the case moved from personal story to clinical data point.
- It was not presented as a cure.
- The reported hold was long enough to start a broader conversation — and a trial.
What this means: the numbers are the story — a prognosis of months, a response measured in years. Whether that gap can be repeated is the question the trial must answer.
How did Richard Scolyer change melanoma treatment?
Melanoma is a cancer Australia knows well, and Scolyer was one of the people who changed what a melanoma diagnosis could mean.
Groundbreaking immunotherapy research
- He helped establish immunotherapy as a life-saving treatment for melanoma (VCCC Alliance (Victorian cancer research alliance))
- The BBC linked his brain cancer treatment to the scientific breakthroughs he and Georgina Long made in skin cancer research (BBC News (UK public broadcaster))
For a long time, advanced melanoma carried a very short outlook. The work Scolyer helped lead moved the field from chemotherapy-only options toward immunotherapy regimens that are now part of standard care.
Global impact on melanoma care
2024: Australian of the Year ·
Legacy: Clinical trial adapting his glioblastoma protocol
The award recognised not just a researcher but a public communicator. By taking his case public, Scolyer turned a personal diagnosis into a national conversation about what melanoma research had already achieved.
The trade-off: melanoma’s gains took years of clinical evidence to become routine. Glioblastoma patients don’t have years to wait, which is why Scolyer’s case compressed the timeline — for better and for risk.
What is the latest on Richard Scolyer’s health?
The public record ends where his family’s open letter begins: with a diagnosis that was never going to be reversed, and a legacy that was never going to be simple.
Final months
- An open letter to Australians, released after his death, noted that he left behind his wife and three children (ABC News (Australian public broadcaster))
The public record of his final period is dominated by the family’s letter and by institutional tributes. His death on June 7, 2026, came three years after the diagnosis — the timeline is laid out below.
Legacy and memorials
- A state funeral was offered by Prime Minister Anthony Albanese (SBS News (multilingual broadcaster))
- A clinical trial adapting his glioblastoma treatment program is the main continuation of his work
The difference between a memorial and a legacy is whether the work continues. Scolyer’s case produced both: the public tributes on one side, the clinical trial on the other.
The trial adapting Scolyer’s protocol now carries the expectations. The first data will answer whether the strategy that worked in his case can work in others.
Related reading:
- Olivia Newton-John’s Death: Cause, Family, and Lasting Legacy
- Michael Landon: Death, Cause, Family, Net Worth, and Career
Why this matters: the open letter carries the family’s voice, but the trial carries the science. One is a goodbye; the other is a next step.
Key dates in Richard Scolyer’s life
Five dates, one pattern: a three-year stretch in which a researcher’s own body became the fastest-moving case in his field.
| Date | Event |
|---|---|
| 1966 | Born |
| June 2023 | Diagnosed with grade four glioblastoma (The Scientist (life-science magazine)) |
| 1990s–2020s | Career in melanoma research and immunotherapy development |
| 2024 | Named Australian of the Year |
| June 7, 2026 | Died in Sydney at age 59 (BBC News (UK public broadcaster)) |
The takeaway: three years separated the diagnosis from the death, against a forecast of six to eight months. The difference was the experiment he agreed to run on himself.
What’s confirmed and what’s still unclear
Two lists emerge from the record: what sources agree on, and what the public never learned.
Confirmed facts
- He was a leading melanoma pathologist and researcher (Beat Melanoma (Australian melanoma charity))
- He died in 2026 (Beat Melanoma (Australian melanoma charity))
- He shared his brain cancer journey on Facebook (Richard Scolyer’s Facebook page (personal blog))
What’s unclear
- His wife’s profession
- Ages of his three children
- Which elements of the experimental protocol will work for other patients
The split matters: confirmed facts anchor the public record, but the open questions — what exactly he received, what exactly it did — will be answered by the trial, not the tributes.
Tributes and memories
Three voices capture the range of the response: a charity, a research alliance, and the patient himself.
“Richard was one of the most distinguished figures in melanoma research globally; a scientist, clinician, and tireless advocate.”
— Beat Melanoma (Australian melanoma charity), tribute
“Professor Scolyer transformed melanoma care through groundbreaking research that helped establish immunotherapy as a life-saving treatment for many patients.”
— VCCC Alliance (Victorian cancer research alliance), news statement
“Sharing my journey with brain cancer in the hope of contributing to better outcomes for all.”
— Richard Scolyer’s Facebook page (personal blog)
What binds the tributes: each one describes a researcher who treated his own illness as part of the work. The consistency across those voices is part of his legacy.
The takeaway
Richard Scolyer’s story is not a clean victory narrative. An aggressive brain cancer ended his life on June 7, 2026, and no amount of framing changes that. But the sequence he helped create — a diagnosis, a public chronicle, an experimental protocol, and a clinical trial — gave glioblastoma researchers something they rarely get: a visible, documented case with nearly two years of data. For the Australian researchers now running the trial his case inspired, the task is clear: keep testing the protocol until it either works broadly or fails honestly — because the alternative is the six-to-eight-month prognosis that Scolyer spent his final years refusing to accept.
iapcentral.org, theconversation.com, nytimes.com, nine.com.au, melanoma.org.au
Frequently asked questions
Is Richard Scolyer’s wife a doctor?
No public source has confirmed her profession. The open letter released after his death referred to his wife and children, without naming her field of work.
How old are Richard Scolyer’s children?
Their ages were not published. The open letter confirmed that Scolyer left behind three children.
What is Richard Scolyer’s family like?
Scolyer was a husband and father of three. On his public Facebook blog, he described the treatment journey as a way to contribute to better outcomes for other patients.
Why did Bob Marley not treat his melanoma?
Bob Marley’s melanoma — which began under a toenail — was left untreated after he declined surgery in the late 1970s, and he died in 1981. Historical accounts commonly trace that decision to his Rastafarian beliefs and a deep distrust of medical intervention, though the exact reasoning remains debated. The case is often cited as a reminder of what happens when melanoma is not treated early.
What is the newest breakthrough in melanoma treatment?
The most direct recent breakthrough connected to Scolyer is the protocol he received: combination checkpoint inhibitors given before surgery, making him the first glioblastoma patient treated this way (The Pathologist (pathology industry publication)).
What is the Brainstorm book about?
Brainstorm is the book tied to Richard Scolyer’s brain cancer journey, written from the perspective of the researcher who became the patient. It pairs his personal account with the science behind his experimental treatment.
Who is the leading melanoma expert in Australia?
For much of the past two decades, that title most often fell to Professor Richard Scolyer. His colleague Professor Georgina Long worked alongside him on the immunotherapy research, and the VCCC Alliance credits Scolyer with helping establish immunotherapy as a life-saving treatment for melanoma (VCCC Alliance (Victorian cancer research alliance)).
The pattern in these answers: the public record is detailed on research, sparse on family, and clear on the legacy — Scolyer’s case is now a trial, not just a story.
Related stories
James Mitchell is Editor-in-Chief at Aussie Insightly, overseeing editorial standards, publication decisions and corrections.